WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced Cancers

Japanese Journal of Cancer and Chemotherapy

Volumn 37, Issue 12, 2010, Pages 2240-2242

  Kato, Yoichi ^a  

^a Shin Yokohama Kato Clinic   (Japan)

Author keywords

Dendritic cell therapy; WT1 peptide

Indexed keywords

DENDRITIC CELL VACCINE; HLA A2 ANTIGEN; HLA A24 ANTIGEN; WT1 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; DENDRITIC CELL; ESOPHAGUS CANCER; FEMALE; HUMAN; LUNG CANCER; MALE; MONOCYTE; OVARY CANCER; PANCREAS CANCER; SARCOMA; T LYMPHOCYTE; UTERUS CANCER; VACCINATION;

EID: 84866609320     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Oka Y, Tsuboi A, Taguchi T, et al: Induction of WTi (Wilms' tumor gene) -specific cytotoxic T lymphocytes by WTi peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101 (38): 13885-13890, 2004. (Pubitemid 39298502)
2. Nagayama II, Sato K, Morishita M. et al: Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res 13(5): 521-530,2003. (Pubitemid 37266955)